Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (329)	6/19/2004 6:28:08 PM
From: Icebrg	Read Replies (1) \| Respond to of 590

At the Needham presentation Withy had some words for partnered programs. Pfizer has got three mAbs in the clinic by now and Withy made the following observation. Three Pfizer products are in the clinic. Including the first two, an antibody to CTLA4 and the second product - an antibody to the EGF1-receptor. Pfizer presented at ASCO last week some very interesting data on the antibody to CTLA-4, which they now moved into phase II clinical trials in malignant melanoma. Some of the most mumble, mumble quite interesting data we have seen quite in a while in that indication This is of course interesting as it appears to be more or less a copy of the program that is running at Medarex. And for which Medarex just was awarded Orphan Drug Status. Pfizer did indeed report some very encouraging data from their dose-escalating study. Some of the efficacy data as presented at ASCO: (From the audio+slide presentation available at) asco.org 1 complete response 24+ months 1 complete response 15+ months 1 surgical complete response 13+ months 1 partial response 15+ months 1 partial response 14+ months 5 patients with stable disease from 10 to 28+months There were all in all 34 melanoma patients treated in this study. Some of them most probably at sub-therapeutic dosages as this was a dose-escalation study. Erik